UBS Upgrades Biogen Stock to 'Buy' Rating

UBS has upgraded its rating for pharmaceutical company Biogen to 'Buy,' setting a new price target of $225. The investment bank suggests that the next 12 months could see a series of pipeline catalysts for the stock, making it an attractive investment relative to its peers.

22 Apr, 11:58 — 22 Apr, 11:58

Post Share

Sources

Showing 1 of 2 sources

cnbcMostly Factual131d ago

This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce

The investment bank upgraded the pharmaceutical name to buy from neutral.

Read full article →

Coverage Timeline

First report: cnbc · 22 Apr, 11:58|Full coverage: 2 · 2h|Window: 2h

Left-leaningCenterRight-leaning

cnbc22 Apr, 11:58First to report

This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce

2h later

Yahoo22 Apr, 14:27Latest update

UBS Upgrades Biogen Stock to 'Buy' Rating

Sources

This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce

Coverage Timeline

This pharmaceutical stock is cheap relative to peers. UBS thinks it's due for a bounce

UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?

Related Stories

Lionel Richie Hospitalized in ICU Following St. Louis Concert

Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue

Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases

England Pharmacies to Offer Free Quick Cholesterol Screening Tests